Bivalirudin vs Eptifibatide
Research Verdict
Eptifibatide is the stronger research reference for the stated comparison criteria. Bivalirudin: direct thrombin inhibitor, HORIZONS-AMI (n=3,602) showing reduced bleeding vs.
Quick Answers
Which is better, Bivalirudin or Eptifibatide?
Eptifibatide is the stronger research reference for the stated comparison criteria. Bivalirudin: direct thrombin inhibitor, HORIZONS-AMI (n=3,602) showing reduced bleeding vs.
What is the key difference between Bivalirudin and Eptifibatide?
Bivalirudin inhibits thrombin directly (coagulation cascade); eptifibatide inhibits platelet aggregation via GP IIb/IIIa receptor blockade - different targets in hemostasis (coagulation vs. platelet function) often used in complementary clinical contexts.
Evidence Comparison
Bivalirudin: direct thrombin inhibitor, HORIZONS-AMI (n=3,602) showing reduced bleeding vs. heparin+GP IIb/IIIa. Eptifibatide: GP IIb/IIIa inhibitor, PURSUIT trial (NEJM 1998, n=10,948) and ESPRIT trial showing reduced ischemic events in PCI. Both have large Phase 3 datasets; eptifibatide has the larger total trial enrollment.
Evidence Context Favoring Bivalirudin
PCI anticoagulation research prioritizing reduced bleeding risk profile (HORIZONS-AMI advantage).
Evidence Context Favoring Eptifibatide
Acute coronary syndrome or PCI research where platelet aggregation inhibition is the primary mechanism of interest.
Side-by-Side Snapshot
| Evidence grade | Bivalirudin: Level A Eptifibatide: Level A |
|---|---|
| Research status | Bivalirudin: FDA Approved Eptifibatide: FDA Approved |
| Primary category | Bivalirudin: Healing & Recovery Eptifibatide: Healing & Recovery |
| Cited studies | Bivalirudin: 3 Eptifibatide: 3 |